Ihr neues Infoportal.

Hepatitis Delta in Österreich: Epidemiologie, Screening & Therapie

Lebererkrankungen

Bulevirtid bei Patienten mit chronischer Hepatitis Delta: Klinische Studien und Real-World-Daten

Lebererkrankungen

Hepatitis Delta Fallbesprechung Patient 2

Lebererkrankungen

Hepatitis Delta Fallbesprechung Patient 1 – Teil 1: Management der Hepatitis B

Lebererkrankungen

Hepatitis Delta Fallbesprechung Patient 1 – Teil 2: Nicht-invasive Tests bei der Hepatitis Delta

Lebererkrankungen

Hepatitis Delta Fallbesprechung Patient 1 – Teil 3: Therapie mit Bulevirtid

Lebererkrankungen

IAS 2023 - Exchange: Gewichtsveränderung

HIV

IAS 2023 - Exchange: Rapid Start

HIV

IAS 2023 - Exchange: Resistenzen

HIV

Übersicht zur aktuellen Therapielandschaft bei COVID-19 sowie ein Überblick zu den rezenten Daten von Remdesivir von Dr. Mario Karolyi

COVID-19

Voeller, A. et al: Total HCV patients treated with direct acting antivirals since 2014

10.-14.11.2023 / AASLD

Lebererkrankungen

Rieke, A. et al: Real-World Effectiveness and Tolerability of Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) in Treatment-Experienced (TE) People With HIV With a History of CKD

02.-05.11.2023 / ID Week

HIV

Sabranski, M. et al: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Antiretroviral Treatment-Naïve (TN) and -Experienced (TE) People With HIV (PWH): 3-Year Effectiveness and Safety Outcomes in the BICSTaR Observational Cohort.

18.-21.10.2023 / EACS 2023

HIV

Esser, S. et al: Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment-Experienced People With HIV (PWH) With Baseline Symptoms of Depression/Anxiety and/or Insomnia in the Observational BICSTaR Study.

18.-21.10.2023 / EACS 2023

HIV

Andreatta, K. et al: Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Versus Dolutegravir (DTG) Based 3 Drug Regimens in Adults With HIV Who Have Suboptimal Antiretroviral Adherence

11.-15.10.2023 / ID Week

HIV

Lampertico P. et al. Continued Treatment of Early Nonresponders or Partial Virologic Responders With Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta Through Week 96 Leads to Improvement in Virologic and Biochemical Responses

21.-24.06.2023 / EASL

Lebererkrankungen

Lim Y-S. et al. Long term safety profile of tenofovir alafenamide in chronic hepatitis B patients; final 8-year results of 2 phase 3 studies

21.-24.06.2023 / EASL

Lebererkrankungen

Esteban R. et al. Concomitant use of Proton Pump Inhibitors and Sofosbuvir/Velpatasvir: Evidence from Randomized Clinical trials and Real-World Data

21.-24.06.2023 / EASL

Lebererkrankungen

Santos, J. R. et al: The REDPINE Study: Efficacy and Safety of Remdesivir in People With Moderately and Severely Reduced Kidney Function Hospitalised for COVID-19 Pneumonia

15.-18.04.2023 / ECCMID

COVID-19

Lee, E. et al: Remdesivir Reduces Readmission in Immunocompromised Adult Patients Hospitalised With COVID 19

15.-18.04.2023 / ECCMID

COVID-19